Latent autoimmune diabetes and ketosis-prone diabetes

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Adult diabetes does not divide neatly into lean autoimmune and overweight insulin-resistant categories. Slowly progressive autoimmune diabetes may maintain enough secretion to avoid insulin for months after diagnosis and is often called LADA, although definitions and management boundaries are not universally standardised. The practical issue is not the label but recognition that beta-cell reserve is declining. A person treated as type 2 who loses weight, develops ketones or shows unexpectedly poor response despite adherence needs prompt review. Autoantibodies support autoimmune mechanism, and C-peptide later quantifies remaining secretion. If insulin deficiency is clinically significant, insulin should start without waiting for a particular antibody result or an arbitrary duration of non-insulin treatment.

Ketosis-prone diabetes is a different clinical pattern: DKA occurs, yet after acute treatment and resolution of glucose toxicity some people recover meaningful insulin secretion. Specialist classification often considers autoantibody status and beta-cell reserve, but the acute team should not predict remission from appearance or background. Everyone with DKA receives full protocol treatment and discharge insulin unless the diabetes service deliberately changes the plan. C-peptide during severe hyperglycaemia can be misleadingly low because beta cells are metabolically suppressed; reassessment after recovery is more informative. If insulin withdrawal is considered, it should be gradual, supported by stable glucose, adequate reserve, education, ketone testing and close follow-up. Relapse can occur during illness or with worsening beta-cell function, so the person retains an emergency plan even after insulin independence.

Key points

Latent autoimmune diabetes in adults describes slower autoimmune beta-cell loss that initially resembles type 2 diabetes but progresses towards insulin dependence.
GAD antibodies are commonly detected; local panels may include IA-2 or ZnT8, and testing is most informative close to diagnosis when clinical classification is uncertain.
Rapid deterioration, catabolic weight loss, ketosis, personal autoimmunity or failure of non-insulin therapy should prompt reassessment for autoimmune diabetes.
Ketosis-prone diabetes presents with DKA but may later show substantial endogenous insulin reserve and an antibody-negative phenotype; acute DKA care is unchanged.
Classify ketosis-prone presentations after glucose toxicity resolves, using diabetes-specific antibodies and C-peptide measured with paired glucose under specialist supervision.
Some people with recovered beta-cell reserve can reduce or stop insulin, but only through a planned process with glucose and ketone surveillance and rapid restart criteria.
Avoid using ethnicity or body size as a deterministic diagnostic rule; both conditions occur across diverse populations and individual physiology must be measured.
An SGLT2 inhibitor is hazardous when effective insulin deficiency or recurrent ketosis is possible and should not be introduced casually during diagnostic uncertainty.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Slowly progressive autoimmunity

Adult autoimmune diabetes destroys beta cells gradually, allowing enough early insulin secretion to resemble type 2 diabetes before reserve declines.

Ketosis-prone beta-cell dysfunction

Some adults present with severe but potentially reversible insulin secretory failure during glucose toxicity, with variable autoantibody status and later recovery.

Mixed metabolic susceptibility

Insulin resistance and body habitus can coexist with autoimmune or ketosis-prone mechanisms, so appearance alone cannot reliably classify the diabetes.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Insulin reserve becomes inadequate
Autoimmune loss or acute beta-cell suppression reduces endogenous insulin below that required to restrain glucose production and lipolysis.
2
Hyperglycaemia and ketosis emerge
Rising glucose creates osmotic symptoms, while severe deficiency permits fatty-acid conversion to ketones and potentially DKA.
3
Reserve may follow different trajectories
Autoimmune secretion generally declines, whereas ketosis-prone secretion may improve after glucose toxicity resolves, making later C-peptide reassessment informative.
4
Relapse remains possible
Illness or progressive beta-cell failure can again exceed reserve, so ketone education and an emergency plan remain important even after insulin independence.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Slow autoimmune progression

Adult onset followed by escalating glucose, weight loss or early insulin need despite appropriate type 2 therapy suggests autoimmune decline, particularly with thyroid, coeliac or other autoimmune disease.

Ketosis-prone presentation

DKA at diagnosis or after a stressor can coexist with phenotypic features of type 2 diabetes; later recovery of secretion cannot be inferred until metabolic stabilisation and follow-up testing.

Insulin-deficiency symptoms

Polyuria, thirst, nocturia, blurred vision, fatigue, catabolic weight loss and ketones indicate inadequate effective insulin and override assumptions based on age or adiposity.

Classification mismatch

Repeated ketosis, unexpected hypoglycaemia on small insulin doses, preserved secretion years later or a dominant family pattern may indicate an alternative mechanism and merits specialist re-evaluation.

Relapse risk

Illness, glucocorticoid exposure, missed treatment or rising glucose after a remission phase can herald recurrent ketosis; early ketone testing and access to the diabetes team are essential.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Diabetes-specific autoantibody panelFirst step
Why
Identify autoimmune beta-cell disease in an adult whose diabetes type is uncertain.
Interpretation and limitations
Positive GAD, IA-2 or ZnT8 antibodies support autoimmune diabetes and future insulin-dependence risk. A negative panel does not prove ketosis-prone type 2 or exclude all autoimmunity.
02
Non-fasting C-peptide with paired glucose
Why
Measure residual endogenous insulin production after acute glucose toxicity has resolved.
Interpretation and limitations
Low secretion despite adequately stimulating glucose supports ongoing insulin dependence. Meaningful reserve can support cautious treatment simplification, but must be integrated with antibodies, history and ketone risk.
03
Blood ketones and venous blood gas
Why
Diagnose DKA at presentation or relapse rather than relying on glucose magnitude.
Interpretation and limitations
Ketonaemia with metabolic acidosis requires immediate DKA management. Modest ketones without acidosis prompt hydration, insulin-plan review and close reassessment according to sick-day guidance.
04
HbA1c and glucose profile
Why
Estimate preceding hyperglycaemia and establish a baseline for recovery or relapse monitoring.
Interpretation and limitations
HbA1c cannot distinguish LADA from ketosis-prone diabetes. Rapid sensor or capillary improvement after insulin may reflect reversal of glucose toxicity rather than a permanent cure.
05
Renal, thyroid and coeliac assessment
Why
Identify treatment constraints and autoimmune comorbidity relevant to an adult autoimmune phenotype.
Interpretation and limitations
Renal impairment changes insulin clearance; thyroid or coeliac disease can destabilise glucose and strengthen an autoimmune context, but neither alone defines diabetes type.
06
Targeted monogenic or pancreatic evaluation
Why
Pursue alternative classification when family history, exocrine symptoms, imaging history or syndromic features are compelling.
Interpretation and limitations
Testing should follow specialist criteria because monogenic, mitochondrial and pancreatogenic diabetes change treatment and family counselling; broad unselected testing creates uncertain variants.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Type 2 diabetes

Stable response to non-insulin treatment with preserved secretion supports type 2 disease, but weight and age alone do not exclude autoimmunity.

Classic type 1 diabetes

Rapid permanent insulin dependence, autoimmune markers and very low reserve favour conventional type 1 diabetes over a remitting ketosis-prone pattern.

Monogenic diabetes

Strong multigenerational early-onset diabetes, retained C-peptide and negative autoantibodies suggest a single-gene disorder with different treatment implications.

Pancreatic diabetes

Pancreatitis, pancreatic surgery, malabsorption or imaging abnormalities point to loss of endocrine tissue from exocrine pancreatic disease.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01AcuteTreat DKA before subclassificationFirst stepAn adult with any prior diabetes label has ketonaemia, acidosis and compatible illness.

1Start the current adult DKA protocol with fluid, fixed-rate insulin, potassium monitoring and precipitant treatment, regardless of body habitus or presumed type.
2Continue or establish background insulin according to the pathway and involve the inpatient diabetes team early for transition and education.
3Record diagnostic uncertainty and plan antibody and later C-peptide review, but discharge only with a safe insulin and ketone strategy owned by a named service.

02AutoimmuneReclassify suspected LADAAn adult labelled type 2 shows early failure, catabolic symptoms, ketones or autoimmune clues.

1Assess current metabolic safety first, checking blood ketones and urgent biochemistry if symptomatic, and begin insulin promptly when deficiency is likely.
2Request diabetes-specific autoantibodies and review medicine, family and autoimmune history; use paired C-peptide later if uncertainty remains.
3Provide type 1-relevant insulin, hypoglycaemia and sick-day education whenever treatment depends on insulin, while communicating that terminology and progression vary.

03RecoveryAssess insulin withdrawal after ketosis-prone DKAA person is clinically stable after DKA and insulin requirements fall as glucose toxicity resolves.

1Allow metabolic recovery, then measure antibodies and stimulated or non-fasting C-peptide with paired glucose through specialist care.
2If reserve is adequate and glucose remains stable, reduce insulin stepwise with frequent glucose review, ready access to ketone testing and explicit relapse thresholds.
3Maintain long-term follow-up for glycaemia and complications, reconsider insulin promptly during illness or deterioration, and avoid medicines that amplify ketosis risk without expert justification.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Replaces inadequate insulin in LADA and provides safe treatment after a ketosis-prone presentation while beta-cell reserve is being established.

Basal-bolus insulin

Use an individual specialist-led basal and mealtime regimen, titrated from glucose patterns, carbohydrate intake, renal function and hypoglycaemia risk; continue basal insulin during illness.

Requirements may fall substantially after reversal of glucose toxicity, creating hypoglycaemia unless reviewed frequently. Any planned withdrawal needs specialist supervision and a ketone safety plan.

Stops ketogenesis and corrects the insulin-deficient metabolic state regardless of the eventual diabetes subtype.

Intravenous insulin for DKA

Follow the current JBDS-aligned fixed-rate infusion and local protocol alongside fluid, potassium and glucose-containing solutions until biochemical resolution criteria are met.

Do not stop because plasma glucose normalises while ketones or acidosis persist. Monitor potassium closely and overlap the transition to subcutaneous insulin safely.

May address insulin resistance in antibody-negative ketosis-prone diabetes or mixed physiology but does not replace insulin during active deficiency.

Metformin after specialist reassessment

If insulin resistance remains relevant and renal function permits after stabilisation, introduce or resume a low oral dose with food and titrate using the current type 2 pathway.

Withhold during severe dehydration, hypoxia or acute kidney injury. Gastrointestinal effects and vitamin B12 deficiency occur, and apparent type 2 features must not delay insulin when ketones recur.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Diabetic ketoacidosis

Insulin reserve can fall below the threshold needed to suppress ketogenesis, producing dehydration, acidosis and electrolyte depletion.

Recurrent misclassification

Assuming all adult diabetes with higher body mass is type 2 can delay insulin, while premature withdrawal after DKA can trigger relapse.

Long-term vascular disease

Persistent hyperglycaemia produces the same retinal, renal, neurological and cardiovascular risks as other diabetes types, requiring ongoing surveillance.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During early classification, review glucose or sensor data, insulin dose, weight and symptomatic ketones often enough to detect both recovery and renewed deficiency.
Repeat C-peptide only when the result will change a supervised treatment decision and always record the paired glucose and time from acute DKA.
Track severe hypoglycaemia as insulin needs decline after glucose toxicity, reducing doses proactively rather than waiting for recurrent events.
Maintain annual renal, retinal, foot, blood pressure and lipid surveillance according to the person's diabetes and complication risk.
For autoimmune diabetes, reassess thyroid and coeliac disease when indicated and support the full type 1 sick-day and technology needs.
After insulin withdrawal in ketosis-prone diabetes, preserve rapid diabetes-team access, blood ketone supplies and a written illness or relapse plan.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

LADA is a trajectory

The clinically useful insight is progressive autoimmune loss, not debating a rigid label. Falling reserve and rising ketone risk should drive timely insulin and education.

C-peptide can recover

Severe glucotoxicity suppresses secretion, so a value taken during DKA may exaggerate permanent failure. Reassessment after stabilisation prevents premature lifelong classification.

Remission is conditional

Insulin independence after ketosis-prone DKA reflects recovered reserve, not immunity from future ketosis. Infection or metabolic decline can expose deficiency again.

Antibodies and reserve answer different questions

Autoantibodies indicate immune mechanism; C-peptide measures current secretion. Their combination is more informative than treating either as a complete diagnostic label.

Phenotype is not destiny

Age, ancestry and body habitus alter prior probability but do not determine pathophysiology. Individual biochemical evidence protects patients from stereotyping and unsafe withdrawal.

11Common pitfallsFrequent interpretation and management errors.

01
Calling an adult type 2 solely because they have obesity despite weight loss, ketones and rapid treatment failure.
02
Using C-peptide obtained during DKA as definitive evidence of permanent beta-cell failure.
03
Withdrawing insulin immediately after DKA because glucose improves on small doses without specialist testing or follow-up.
04
Assuming negative GAD antibodies exclude autoimmune diabetes without considering the full panel, timing and phenotype.
05
Starting an SGLT2 inhibitor during unresolved classification and recurrent ketosis risk.
06
Using ethnicity as a substitute for antibody, C-peptide and clinical evidence.